New Zealand July trade balance: deficit NZD 1.949 bln; June balance revised from a NZD 23 mln surplus to a NZD 237 mln deficit.

Futu Holdings (FUTU.O) Q2 2026 total trading value rose 78.8% YoY to HKD 6.42 tln. Reported net profit rose 41.6% YoY to HKD 3.6419 bln (USD 464.4 mln). Adjusted (non‑GAAP) net profit rose 40.1% YoY to HKD 3.7251 bln (USD 475.0 mln).

Xiansheng Pharmaceutical on Aug. 20 said it has struck a strategic cooperation with Ruiyang (Shandong) Biopharmaceutical on the domestic Class-1 biologic new drug Kulaivebai mAb injection. Under the deal Xiansheng will hold exclusive commercialization rights in Greater China. The marketing authorisation application has been accepted by the National Medical Products Administration’s Center for Drug Evaluation (CDE) and placed in priority review. The company said the collaboration will strengthen its anti-infectives product portfolio.